Gilead-Arcus Biosciences Partnered Lung Cancer Therapy Shows Continuous Positive Efficacy Measures


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


  • Gilead Sciences Inc (NASDAQ:GILD) and Arcus Biosciences (NASDAQ:RCUSannounced an update from the fourth interim analysis of Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. 
  • ARC-7 is evaluating the combinations of anti-TIGIT antibody domvanalimab plus zimberelimab (doublet) and domvanalimab plus zimberelimab and etrumadenant (triplet) versus zimberelimab alone.
  • Related: Arcus Posts Encouraging Data For Domvanalimab-Based Regimes In Lung Cancer Settings.
  • For the current interim analysis, efficacy was evaluated in study patients who had at least 13 weeks of potential follow-up and were eligible for at least two imaging scans (n=133). 
  • Both domvanalimab combinations showed clinically meaningful differentiation compared to zimberelimab monotherapy across multiple efficacy measures, including objective response rates (ORR), progression-free survival (PFS), and six-month landmark PFS.
  • No unexpected safety signals were observed across the three study arms. Both domvanalimab-containing arms were generally well tolerated.
  • Detailed results from this fourth interim analysis and exploratory analysis on 12 patients who crossed over from zimberelimab monotherapy arm to triplet therapy will be presented at the Monthly Plenary Series next month.
  • Price Action: RCUS shares are up 5.20% at $28.10, and GILD stock is up 0.09% at $86.34 on the last check Monday.

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechLarge CapNewsHealth CareMoversTrading IdeasGeneralBriefs